CDK4 and triple-negative breast carcinoma: In particular, the sequential combination of CDK4/6 inhibitors and paclitaxel-based chemotherapy produced antiproliferative and pro-apoptotic effects in TNBC (triple-negative breast cancer) cell lines associated with an impairment of glucose metabolism [30], and recently, the efficacy of the simultaneous combination of gemcitabine/cisplatin-based chemotherapy and CDK4/6 inhibitors has been demonstrated also in biliary tract cancers [31].